We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

61 hedge funds and large institutions have $85.6M invested in Cartesian Therapeutics in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

47% more capital invested

Capital invested by funds: $58.3M → $85.6M (+$27.3M)

16.7% more ownership

Funds ownership: 1.13% → 17.82% (+17%)

12% less funds holding

Funds holding: 69 → 61 (-8)

26% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 27

Holders
61
Holders Change
-8
Holders Change %
-11.59%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
25
Reduced
10
Closed
27
Calls
$114K
Puts
–
Net Calls
+$114K
Net Calls Change
+$97K

Top Buyers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
+$6.2M
2
JP Morgan Chase
JP Morgan Chase
New York
+$6.18M
3
IC
Ikarian Capital
Texas
+$5.78M
4
BlackRock
BlackRock
New York
+$3.96M
5
LGM
Logos Global Management
California
+$2.15M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$23M
2
Millennium Management
Millennium Management
New York
-$647K
3
CM
CM Management
Florida
-$199K
4
Invesco
Invesco
Georgia
-$159K
5
Jane Street
Jane Street
New York
-$124K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$13.8M +$759K +31,807 +7%
BlackRock
2
BlackRock
New York
$11M +$3.96M +165,797 +69%
JP Morgan Chase
3
JP Morgan Chase
New York
$8.27M +$6.18M +258,825 +545%
AG
4
Artal Group
Luxembourg
$8.23M -$24 -1 -0%
MB
5
MPM BioImpact
Massachusetts
$7.01M +$6.2M +259,696 New
IC
6
Ikarian Capital
Texas
$6.55M +$5.78M +242,370 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$6.39M +$624K +26,153 +12%
State Street
8
State Street
Massachusetts
$4.15M +$2.01M +84,104 +121%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$3.59M +$1.19M +49,665 +60%
EAM
10
Erste Asset Management
Austria
$3.31M +$362K +15,163 +14%
LGM
11
Logos Global Management
California
$2.43M +$2.15M +90,000 New
BFM
12
Boothbay Fund Management
New York
$1.85M +$1.64M +68,540 New
N
13
Nuveen
North Carolina
$939K +$439K +18,406 +113%
LSAG
14
Lake Street Advisors Group
New Hampshire
$855K +$755K +31,644 New
Northern Trust
15
Northern Trust
Illinois
$835K -$6.16K -258 -0.8%
Marshall Wace
16
Marshall Wace
United Kingdom
$811K +$717K +30,038 New
SFM
17
Sphera Funds Management
Israel
$677K +$578K +24,234 +2,899%
DFG
18
Delphi Financial Group
Delaware
$595K – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$538K +$223K +9,339 +88%
Charles Schwab
20
Charles Schwab
California
$514K +$196K +8,204 +76%
Renaissance Technologies
21
Renaissance Technologies
New York
$461K -$33.4K -1,401 -8%
CSS
22
Cubist Systematic Strategies
Connecticut
$351K +$311K +13,010 New
BCM
23
Bridgeway Capital Management
Texas
$275K – – –
TFCP
24
Twin Focus Capital Partners
Massachusetts
$270K +$239K +10,000 New
RhumbLine Advisers
25
RhumbLine Advisers
Massachusetts
$229K +$99.2K +4,158 +96%
1
2 3 4

RNAC Hedge Fund Activity: Q2 2024 in Review

61 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2024, worth a combined $85.6M — up 47% from $58.3M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RNAC and 20 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 25 added.

The largest buyer was MPM BioImpact, opening a new position worth an estimated $6.2M. The largest seller was Goldman Sachs, exiting entirely with an estimated $23M sold.

  • 61 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2024, down from 69 in Q1 2024.
  • Funds reported $85.6M of Cartesian Therapeutics stock for Q2 2024, up 47% quarter-over-quarter.
  • 20 funds opened new Cartesian Therapeutics positions in Q2 2024 and 27 closed out, a net change of -7 holders.
  • The largest Cartesian Therapeutics buyer in Q2 2024 was MPM BioImpact, an estimated $6.2M added.
  • The largest Cartesian Therapeutics seller in Q2 2024 was Goldman Sachs, an estimated $23M sold.

Based on aggregated 13F filings for Q2 2024.